Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 17.51% to 25.50 as at 11:04 am.
Accomplish Kintor's First Sales Revenue RMB34.23M in 2021
• Upfront payment of out-licensing contract with Fosun Pharma in India and 28 African countries
• Upfront payment of out-licensing contract with Etana in Indonesia
Pioneer of Chinese Innovative Drugs' Globalization
• 3 phase III MRCTs were approved by various countries' administration (FDA included)
• 4 drug candidates（proxalutamide, pyrilutamide, ALK-1 antibody, GT20029）have clinical trials carried out within and out of China.
Kintor said before the start of trading that a clinical trial for its proxalutamide drug candidate had effectively reduced the risk of hospitalization and death in outpatients with mild-to-moderate cases of Covid-19, including patients with high-risk factors such as older age.
